AML is a highly heterogeneous disease, and with the exception of a relatively well defined acute promyelocytic leukemia (APL) characterized by t(15;17)(q22;q21) PML-RARA fusion, it exhibits a highly diverse clinical course and requires different treatment modalities (Liersch et al., 2014). The gene discussed is RARA; the disease is acute promyelocytic leukemia.